SELLAS Life Sciences Group, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
SELLAS Life Sciences Group, Inc. (SLS) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $825.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2019-11-14
- 2018-09-30: Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month $825.00K.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month |
|---|---|
| 2018-09-30 | $825.00K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |